CD19 and Alzheimer disease: The AD-related toxic proteins such as Aβ can stimulate B cells to secrete specific antibodies, and CD19+ total B cells are reduced in the peripheral blood of AD patients, which may reduce the secretion of specific antibodies against AD pathology, thereby exacerbating the development of AD.